Anifrolumab in systemic lupus erythematosus: real-world experience from a single academic tertiary care centre.

IF 3.4 4区 医学 Q2 RHEUMATOLOGY
Paul Classen, Simone Boedecker-Lips, Vanessa Tomalla, Daniel Kraus, Andreas Kommer, Marco Stortz, Arndt Weinmann, Myriam Meineck, Sabrina Saurin, Matthias Plath, Janine Riepl, Julia Weinmann-Menke
{"title":"Anifrolumab in systemic lupus erythematosus: real-world experience from a single academic tertiary care centre.","authors":"Paul Classen, Simone Boedecker-Lips, Vanessa Tomalla, Daniel Kraus, Andreas Kommer, Marco Stortz, Arndt Weinmann, Myriam Meineck, Sabrina Saurin, Matthias Plath, Janine Riepl, Julia Weinmann-Menke","doi":"10.55563/clinexprheumatol/728zl6","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the effectiveness and safety of anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1, on systemic lupus erythematosus (SLE) at a German academic tertiary care centre in a real-life setting.</p><p><strong>Methods: </strong>We evaluated disease activity, clinical course and adverse events in a single-centre prospective observational cohort study of 26 SLE patients at baseline, 3, 6, 9, 12, 18 and 24 months of anifrolumab treatment. The decision to initiate therapy was made according to current guidelines (EULAR 2024).</p><p><strong>Results: </strong>There was a significant reduction in the disease activity indices SLE-Disease Activity Index 2000 (SLEDAI-2k) (6.0±3.9 vs. 2.8±2.6, p≤0.001) and European Consensus Lupus Activity Measurement Index (ECLAM) (1.92 ±1.16 vs. 0.94±0.99, p=0.001) after just three months of treatment. After 12 months, definition of remission in SLE (DORIS) was achieved in 53% of patients and lupus low disease activity state (LLDAS) in 89% of patients. Mucocutaneous manifestations responded quickly and there were significant improvements in fatigue and arthritis/arthralgia. A favourable response was also seen in patients who had received previous therapies or after long duration of the disease. This was accompanied by a reduction in the glucocorticoid dose. Overall, the drug was safe and well tolerated.</p><p><strong>Conclusions: </strong>In our real-world experience, anifrolumab achieved sustained remission after just 3 months of treatment and a significant reduction in disease activity in most patients. These data suggest that SLE patients with active disease benefit from anifrolumab therapy regardless of prior therapies or disease duration.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/728zl6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To evaluate the effectiveness and safety of anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1, on systemic lupus erythematosus (SLE) at a German academic tertiary care centre in a real-life setting.

Methods: We evaluated disease activity, clinical course and adverse events in a single-centre prospective observational cohort study of 26 SLE patients at baseline, 3, 6, 9, 12, 18 and 24 months of anifrolumab treatment. The decision to initiate therapy was made according to current guidelines (EULAR 2024).

Results: There was a significant reduction in the disease activity indices SLE-Disease Activity Index 2000 (SLEDAI-2k) (6.0±3.9 vs. 2.8±2.6, p≤0.001) and European Consensus Lupus Activity Measurement Index (ECLAM) (1.92 ±1.16 vs. 0.94±0.99, p=0.001) after just three months of treatment. After 12 months, definition of remission in SLE (DORIS) was achieved in 53% of patients and lupus low disease activity state (LLDAS) in 89% of patients. Mucocutaneous manifestations responded quickly and there were significant improvements in fatigue and arthritis/arthralgia. A favourable response was also seen in patients who had received previous therapies or after long duration of the disease. This was accompanied by a reduction in the glucocorticoid dose. Overall, the drug was safe and well tolerated.

Conclusions: In our real-world experience, anifrolumab achieved sustained remission after just 3 months of treatment and a significant reduction in disease activity in most patients. These data suggest that SLE patients with active disease benefit from anifrolumab therapy regardless of prior therapies or disease duration.

系统性红斑狼疮的无性抗体:来自单一学术三级护理中心的真实世界经验。
目的:评估anifrolumab(一种针对I型干扰素受体亚基1的人单克隆抗体)在德国学术三级保健中心治疗系统性红斑狼疮(SLE)的有效性和安全性。方法:我们在一项单中心前瞻性观察队列研究中评估了26例SLE患者在基线、3、6、9、12、18和24个月的anfrolumab治疗中的疾病活动性、临床病程和不良事件。启动治疗的决定是根据现行指南(EULAR 2024)做出的。结果:治疗3个月后,疾病活动性指数sle -疾病活动性指数2000 (SLEDAI-2k)(6.0±3.9比2.8±2.6,p≤0.001)和欧洲共识狼疮活动性测量指数(ECLAM)(1.92±1.16比0.94±0.99,p=0.001)显著降低。12个月后,53%的SLE患者达到缓解(DORIS), 89%的患者达到狼疮低疾病活动状态(LLDAS)。粘膜皮肤表现反应迅速,疲劳和关节炎/关节痛有显著改善。在以前接受过治疗或长期患病的患者中也可以看到良好的反应。这伴随着糖皮质激素剂量的减少。总体而言,该药是安全且耐受性良好的。结论:在我们的实际经验中,anfrolumab在仅仅3个月的治疗后就实现了持续缓解,并且在大多数患者中显著降低了疾病活动。这些数据表明,活动性SLE患者无论既往治疗或病程如何,均可从单克隆抗体治疗中获益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
18.90%
发文量
377
审稿时长
3-6 weeks
期刊介绍: Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信